Study finds Mounjaro reduces heart attack risk by 33% in type 2 diabetes patients with heart disease

A study in The BMJ of 53,000 patients reveals that Mounjaro reduces heart attack risks by 33% in type 2 diabetes patients with heart disease compared to sitagliptin. Mounjaro also lowered all-cause mortality and infection-related hospitalizations, though it showed no impact on stroke. Meanwhile, separate data from the University of Pennsylvania and UK regulators highlight potential links between GLP-1 drugs and hair loss.

Mounjaro cardiovascular benefit study

• ▪The BMJ study compared major adverse cardiovascular events between patients starting Mounjaro and patients starting sitagliptin, another common diabetes drug.
• ▪A study published in The BMJ involving nearly 53,000 type 2 diabetes and heart disease patients suggests Mounjaro reduces cardiovascular risks.
• ▪After one year, the risk of major adverse cardiovascular events was 2.9% for patients on Mounjaro compared to 4.4% for those on sitagliptin.

Heart attack risk reduction

• ▪Mounjaro reduced the risk of heart attacks by 33% compared to patients taking sitagliptin, which researchers estimate prevents one case per 70 people.
• ▪The BMJ study found no meaningful difference in stroke cases between patients taking Mounjaro and those taking sitagliptin.

Mortality prevention rates

• ▪Mounjaro treatment prevented one death from any cause for every 122 patients in the study.
• ▪A study published in The BMJ involving nearly 53,000 type 2 diabetes and heart disease patients suggests Mounjaro reduces cardiovascular risks.

GLP-1 hair loss reports

• ▪A July 2026 study of around 50,000 people by the University of Pennsylvania Health System supported a link between GLP-1 drugs and alopecia hair loss.
• ▪The UK Medicines and Healthcare products Regulatory Agency received 399 reports of hair loss relating to tirzepatide so far in 2026, following 541 reports in 2025.

Hospital admission prevention

• ▪A study published in The BMJ involving nearly 53,000 type 2 diabetes and heart disease patients suggests Mounjaro reduces cardiovascular risks.
• ▪Mounjaro lowered hospital admissions due to infections, preventing one admission for every 48 patients.

1 source